Accueil>>Signaling Pathways>> Metabolism>> HSP>>116-9e

116-9e (Synonyms: MAL2-11B)

Catalog No.GC63796

116-9e (MAL2-11B) est un inhibiteur de l'ADNJA1 co-chaperon Hsp70.

Products are for research use only. Not for human use. We do not sell to patients.

116-9e Chemical Structure

Cas No.: 831217-43-7

Taille Prix Stock Qté
5 mg
126,00 $US
En stock
10 mg
225,00 $US
En stock
25 mg
522,00 $US
En stock
50 mg
855,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

116-9e (MAL2-11B) is a Hsp70 co-chaperone DNAJA1 inhibitor. 116-9e inhibits Simian Virus 40 (SV40) replication and DNA synthesis. 116-9e inhibits tumor antigen (TAg)’s endogenous ATPase activity and the TAg-mediated activation of Hsp70[1][2].

116-9e (MAL2-11B) inhibits TAg stimulation of Hsp70 with greater efficacy than MAL3-101, significantly reduces viral replication and DNA synthesis. MAL2-11B also inhibits the activity of the TAg ATPase domain[1]. 116-9e (MAL2-11B; 15 µM; 5 days) significantly reduces the growth of BK virus in a human kidney cell line[1].

[1]. Christine M Wright, et al. Inhibition of Simian Virus 40 replication by targeting the molecular chaperone function and ATPase activity of T antigen. Virus Res. 2009 Apr;141(1):71-80.
[2]. Nitika, et al. Chemogenomic screening identifies the Hsp70 co-chaperone DNAJA1 as a hub for anticancer drug resistance. Sci Rep. 2020 Aug 14;10(1):13831.

Avis

Review for 116-9e

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 116-9e

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.